« Return to News | CROs/Service Providers

Theorem, Charles River collaborate

Friday, September 13, 2013 01:17 PM

CROs Theorem Clinical Research and Charles River Laboratories are collaborating to provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The alliance provides nonclinical testing programs in bioanalysis, immunogenicity and immunology to support clinical trials.

“Charles River develops and validates assays in support of nonclinical programs, and many of these assays can be validated for human matrix and used for analyzing clinical samples,” said  Marc Hoffman, Theorem senior vice president and general manager of biopharmaceutical development.

Charles River’s research models, preclinical testing capabilities and clinical support services are backed by a bioanalysis portfolio for non-GLP and GLP programs. Laboratories are equipped to measure drug and metabolite concentrations in biological matrices and to provide full support for capillary micro sampling and dried blood spot analysis. The variety of advanced equipment ensures the capacity to meet critical deadlines.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.